Shanghai GenePharma Co.

Shanghai, China

Shanghai GenePharma Co.

Shanghai, China
SEARCH FILTERS
Time filter
Source Type

Pei Y.,Jinan University | Xiang Y.-F.,Jinan University | Chen J.-N.,Jinan University | Lu C.-H.,Jinan University | And 17 more authors.
Antiviral Research | Year: 2011

To investigate the anti-herpesvirus mechanism of pentagalloylglucose (PGG), we compared the proteomic changes between herpes simplex virus type 1 (HSV-1) infected MRC-5 cells with or without PGG-treatment, and between non-infected MRC-5 cells with or without PGG-treatment by 2-DE and MS-based analysis. Differentially expressed cellular proteins were mainly involved with actin cytoskeleton regulation. Significantly, PGG can down-regulate cofilin1, a key regulator of actin cytoskeleton dynamics. PGG can inhibit HSV-1-induced rearrangements of actin cytoskeleton which is important for infectivity. Furthermore, cofilin1 knockdown by siRNA also inhibited the HSV-1-induced actin-skeleton rearrangements. Both PGG-treatment and cofilin1 knockdown can reduce HSV-1 DNA, mRNA, protein synthesis and virus yields. Altogether, the results suggested that down-regulating cofilin1 plays a role in PGG inhibiting HSV-1 infection. PGG may be a promising anti-herpesvirus agent for drug development. © 2010 Elsevier B.V.


Jin F.,Jinan University | Li S.,Yamanashi University | Zheng K.,Jinan University | Zhuo C.,Jinan University | And 7 more authors.
PLoS ONE | Year: 2014

Herpes simplex virus type 1 (HSV-1), a member of the herpesviridae, causes a variety of human viral diseases globally. Although a series of antiviral drugs are available for the treatment of infection and suppression of dissemination, HSV-1 remains highly prevalent worldwide. Therefore, the development of novel antiviral agents with different mechanisms of action is a matter of extreme urgency. During the proliferation of HSV-1, capsid assembly is essential for viral growth, and it is highly conserved in all HSV-1 strains. In this study, small interfering RNAs (siRNAs) against the HSV-1 capsid protein were screened to explore the influence of silencing capsid expression on the replication of HSV-1. We designed and chemically synthesized siRNAs for the capsid gene and assessed their inhibitory effects on the expression of target mRNA and the total intracellular viral genome loads by quantitative real-time PCR, as well as on the replication of HSV-1 via plaque reduction assays and electron microscopy. Our results showed that siRNA was an effective approach to inhibit the expression of capsid protein encoding genes including UL18, UL19, UL26, UL26.5, UL35 and UL38 in vitro. Interference of capsid proteins VP23 (UL18) and VP5 (UL19) individually or jointly greatly affected the replication of clinically isolated acyclovir-resistant HSV-1 as well as HSV-1/F and HSV-2/333. Plaque numbers and intracellular virions were significantly reduced by simultaneous knockdown of UL18 and UL19. The total intracellular viral genome loads were also significantly decreased in the UL18 and UL19 knockdown groups compared with the viral control. In conclusion, interfering with UL18 and UL19 gene expression could inhibit HSV-1 replication efficiently in vitro. Our research offers new targets for an RNA interference-based therapeutic strategy against HSV-1. © 2014 Jin et al.


Ren Z.,Jinan University | Li S.,Jinan University | Wang Q.-L.,Jinan University | Xiang Y.-F.,Jinan University | And 6 more authors.
Virologica Sinica | Year: 2011

RNA interference (RNAi) is a process by which introduced small interfering RNA (siRNA) can cause the specific degradation of mRNA with identical sequences. The human herpes simplex virus type 1 (HSV-1) RR is composed of two distinct homodimeric subunits encoded by UL39 and UL40, respectively. In this study, we applied siRNAs targeting the UL39 and UL40 genes of HSV-1. We showed that synthetic siRNA silenced effectively and specifically UL39 and UL40 mRNA expression and inhibited HSV-1 replication. Our work offers new possibilities for RNAi as a genetic tool for inhibition of HSV-1 replication. © 2011 Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg.


Chen X.-L.,Shanghai JiaoTong University | Li X.-Y.,Shanghai JiaoTong University | Qian S.-B.,Shanghai JiaoTong University | Wang Y.-C.,Shanghai JiaoTong University | And 3 more authors.
Biochemical and Biophysical Research Communications | Year: 2012

A series of inhibitors of d-amino acid oxidase (DAAO) are specific in blocking chronic pain, including formalin-induced tonic pain, neuropathic pain and bone cancer pain. This study used RNA interference technology to further validate the notion that spinal DAAO mediates formalin-induced pain. To target DAAO, a siRNA/DAAO formulated in polyetherimide (PEI) complexation and a shRNA/DAAO (shDAAO, with the same sequence as siRNA/DAAO after intracellular processing) expressed in recombinant adenoviral vectors were designed. The siRNA/DAAO was effective in blocking DAAO expression in NRK-52E rat kidney tubule epithelial cells, compared to the nonspecific oligonucleotides. Furthermore, multiple-daily intrathecal injections of both siRNA/DAAO and Ad-shDAAO for 7. days significantly inhibited spinal DAAO expression by 50-80% as measured by real-time quantitative PCR and Western blot, and blocked spinal DAAO enzymatic activity by approximately 60%. Meanwhile, both siRNA/DAAO and Ad-shDAAO prevented formalin-induced tonic phase pain by approximately 60%. Multiple-daily intrathecal injections of siRNA/DAAO and Ad-shDAAO also blocked more than 30% spinal expression of GFAP, a biomarker for the activation of astrocytes. These results further suggest that down-regulation of spinal DAAO expression and enzymatic activity leads to analgesia with its mechanism potentially related to activation of astrocytes in the spinal cord. © 2012 Elsevier Inc.


Mao J.,Chinese Academy of Agricultural Sciences | Zhang P.,Shanghai GenePharma Co Ltd. | Liu C.,Hubei Academy of Agricultural science | Zeng F.,Chinese Academy of Agricultural Sciences
Pesticide Biochemistry and Physiology | Year: 2015

Coatomer and v-ATPase are two genes expressed in insect midgut epithelial cells and their knockdown is lethal to insect larvae. To investigate the RNAi response mediated by multiple siRNA duplexes, partial length cDNA of Helicoverpa armigera coatomer β and v-ATPase A was cloned and siRNA feeding-based RNAi was performed. Simultaneous ingestion of siRNAs specific to the H.armigera coatomer β and v-ATPase A led to co-silencing of the target genes and reduction in larval survival rate and weight gain. These results suggest that silencing two genes by feeding of multiple siRNAs is a good RNAi strategy. © 2014 Elsevier Inc.


PubMed | Hubei Academy of Agricultural science, Chinese Academy of Agricultural Sciences and Shanghai GenePharma Co
Type: | Journal: Pesticide biochemistry and physiology | Year: 2015

Coatomer and v-ATPase are two genes expressed in insect midgut epithelial cells and their knockdown is lethal to insect larvae. To investigate the RNAi response mediated by multiple siRNA duplexes, partial length cDNA of Helicoverpa armigera coatomer and v-ATPase A was cloned and siRNA feeding-based RNAi was performed. Simultaneous ingestion of siRNAs specific to the H.armigera coatomer and v-ATPase A led to co-silencing of the target genes and reduction in larval survival rate and weight gain. These results suggest that silencing two genes by feeding of multiple siRNAs is a good RNAi strategy.


Yao Y.-D.,Sun Yat Sen University | Sun T.-M.,Hefei University of Technology | Huang S.-Y.,Sun Yat Sen University | Dou S.,Hefei University of Technology | And 13 more authors.
Science Translational Medicine | Year: 2012

A major obstacle to developing small interfering RNAs (siRNAs) as cancer drugs is their intracellular delivery to disseminated cancer cells. Fusion proteins of single-chain fragmented antibodies (ScFvs) and positively charged peptides deliver siRNAs into specific target cells. However, the therapeutic potential of ScFv-mediated siRNA delivery has not been evaluated in cancer. Here, we tested whether Polo-like kinase 1 (PLK1) siRNAs complexed with a Her2-ScFv-protamine peptide fusion protein (F5-P) could suppress Her2 + breast cancer cell lines and primary human cancers in orthotopic breast cancer models. PLK1-siRNAs transferred by F5-P inhibited target gene expression, reduced proliferation, and induced apoptosis of Her2 + breast cancer cell lines and primary human cancer cells in vitrowithout triggering an interferon response. Intravenously injected F5-P/PLK1-siRNA complexes concentrated in orthotopic Her2 + breast cancer xenografts and persisted for at least 72 hours, leading to suppressed PLK1 gene expression and tumor cell apoptosis. The intravenously injected siRNA complexes retarded Her2 + breast tumor growth, reduced metastasis, and prolonged survival without evident toxicity. F5-P-mediated delivery of a cocktail of PLK1, CCND1, and AKT siRNAs was more effective than an equivalent dose of PLK1-siRNAs alone. These data suggest that F5-P could be used to deliver siRNAs to treat Her2 + breast cancer.


Lv Q.,Sun Yat Sen University | Li Q.,Sun Yat Sen University | Zhang P.,Shanghai GenePharma Co. | Jiang Y.,Sun Yat Sen University | And 11 more authors.
BioMed Research International | Year: 2015

Background. MicroRNAs can potentially regulate every aspect of cellular activity. In this study, we investigated whether AS pathogenesis involves microRNAs disorders. Result. The expression of 2 microRNAs, hsa-miR-126-3p and hsa-miR-29a, was significantly lower in active AS group before etanercept therapy than in control group. Marched fold changes of them were 3.76 and 16.22. Moreover, expressions of hsa-miR-126-3p and hsa-miR-29a were dramatically upregulated after 12-weeks etanercept treatment. Fold changes were 2.20 and 3.18. All regulations of microRNAs expression mentioned before were statistically significant (fold change >2 and P < 0.05). The expression disorders of the 2 microRNAs did not statistically significantly correlated with BASDAI, CRP, and ESR. Conclusion. AS pathogenesis involved dysregulation of microRNAs. Hsa-miR-126-3p and hsa-miR-29a will probably become the potential biomarkers and provocative therapeutic targets of AS. © 2015 Qing Lv et al.


PubMed | Shanghai GenePharma Co. and Sun Yat Sen University
Type: | Journal: BioMed research international | Year: 2015

MicroRNAs can potentially regulate every aspect of cellular activity. In this study, we investigated whether AS pathogenesis involves microRNAs disorders.The expression of 2 microRNAs, hsa-miR-126-3p and hsa-miR-29a, was significantly lower in active AS group before etanercept therapy than in control group. Marched fold changes of them were 3.76 and 16.22. Moreover, expressions of hsa-miR-126-3p and hsa-miR-29a were dramatically upregulated after 12-weeks etanercept treatment. Fold changes were 2.20 and 3.18. All regulations of microRNAs expression mentioned before were statistically significant (fold change >2 and P < 0.05). The expression disorders of the 2 microRNAs did not statistically significantly correlated with BASDAI, CRP, and ESR.AS pathogenesis involved dysregulation of microRNAs. Hsa-miR-126-3p and hsa-miR-29a will probably become the potential biomarkers and provocative therapeutic targets of AS.

Loading Shanghai GenePharma Co. collaborators
Loading Shanghai GenePharma Co. collaborators